Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

Metformin is widely used to treat hyperglycemia in individuals with type 2 diabetes. Recently the LKB1/AMP-activated protein kinase (LKB1/AMPK) pathway was proposed to mediate the action of metformin on hepatic gluconeogenesis. However, the molecular mechanism by which this pathway operates had rema...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Foretz, Marc, Hébrard, Sophie, Leclerc, Jocelyne, Zarrinpashneh, Elham, Soty, Maud, Mithieux, Gilles, Sakamoto, Kei, Andreelli, Fabrizio, Viollet, Benoit
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Clinical Investigation 2010
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2898585/
https://ncbi.nlm.nih.gov/pubmed/20577053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI40671
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items